Reconstitution and dosing guides
Cited, practical walkthroughs of peptide and GLP-1 reconstitution, dosing, and pharmacology. Every guide links to the matching calculator so you can run your own numbers.
Semaglutide
Where to Inject Semaglutide (Sites and Timing)
A label-cited guide to semaglutide injection sites (abdomen, thigh, upper arm), site rotation, once-weekly timing, and what the label says about a missed dose.
Semaglutide Side Effects (What the FDA Label Lists)
A neutral, label-cited summary of semaglutide side effects, the common GI reactions, the boxed warning on thyroid C-cell tumors, and the labeled warnings.
Semaglutide Dosage Chart (Ozempic and Wegovy)
A cited semaglutide dosage chart with the FDA Ozempic and Wegovy titration schedules, their maximum doses, and how to convert each dose to syringe units.
Ozempic vs Wegovy (Same Drug, Different Label)
Ozempic and Wegovy are both semaglutide. A cited comparison of their indications, maximum doses, schedules, and side effects, with no recommendation.
How to Reconstitute Semaglutide (Step by Step)
A step by step guide to reconstituting semaglutide with bacteriostatic water, the concentration math, and how to convert your dose to syringe units.
Compounded Semaglutide (What It Is and Its Current Status)
A neutral explainer on compounded semaglutide, what it is, why it became common, and the current FDA status after the 2025 shortage resolution. Not advice.
Tirzepatide
What Is Bacteriostatic Water?
Bacteriostatic water is sterile water with 0.9% benzyl alcohol that lets a reconstituted vial be used more than once. How it differs from sterile water and saline.
Tirzepatide vs Semaglutide: Mechanism, Dosing, and Evidence
A cited comparison of tirzepatide and semaglutide covering receptor mechanism, weekly dosing, approved brands, and the SURPASS-2 head to head trial results.
Tirzepatide Side Effects (What the FDA Label Lists)
A neutral, label-cited summary of tirzepatide side effects, the common gastrointestinal reactions, the boxed warning on thyroid C-cell tumors, and the warnings.
Tirzepatide Dosage Chart and Titration Schedule
A cited tirzepatide dosage chart with the FDA titration schedule, the six approved doses, and how to convert each dose to units on a U-100 insulin syringe.
How to Reconstitute Tirzepatide (Step by Step)
A step by step guide to reconstituting tirzepatide with bacteriostatic water, the concentration math, and how to convert your dose to syringe units.
Retatrutide
Retatrutide vs Tirzepatide: Triple vs Dual Agonist
Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist. Tirzepatide is an FDA-approved dual agonist. A cited mechanism and status comparison.
Retatrutide Side Effects: What the Phase 2 Trial Reported
Retatrutide is investigational, so its side effect data comes from trials, not an FDA label. The Phase 2 trial reported dose-related gastrointestinal events.
Retatrutide Results: What the Phase 2 Trial Reported
In the NEJM Phase 2 trial, retatrutide produced dose-dependent weight reduction up to 24.2% at 48 weeks. These are cited trial averages, not a personal prediction.
Retatrutide Dosage: The Phase 2 Trial Escalation Explained
Retatrutide has no FDA-approved dose. See the weekly escalation used in the NEJM Phase 2 trial, why it steps up, and how to convert a dose to syringe units.
How to Reconstitute Retatrutide (Step by Step)
Reconstitute retatrutide by adding bacteriostatic water to the lyophilized vial. The water volume sets the concentration; the calculator gives your units.
BPC-157
How to Reconstitute BPC-157 (Step by Step)
How to reconstitute BPC-157: add bacteriostatic water to the vial, swirl, do not shake. The water volume sets the concentration, and units equal mL x 100.
BPC-157 Side Effects (What the Limited Human Data Show)
BPC-157 has no FDA-established human safety profile. Human data are very limited and most safety information comes from animal studies. A neutral, cited summary.
BPC-157 Dosage (Why There Is No Established Human Dose)
BPC-157 has no FDA-approved or established human dose. Informal protocols cite 250 to 500 mcg daily, which is not a recommendation. How to convert a dose to units.
BPC-157 Benefits (What Preclinical Research Has Studied)
BPC-157 has been studied in animal and cell research for tissue repair and angiogenesis. These are preclinical findings, not proven human benefits.
BPC-157 and TB-500 (Why the Stack Has No Established Dose)
The BPC-157 and TB-500 stack has no controlled human trial and no evidence-based dose ratio. Researchers calculate each compound separately. Neither is FDA-approved.